Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma

被引：0
|
作者：
Schaff, Lauren [1 ]
Fortunato, John [1 ]
Grommes, Christian [1 ]
Gavrilovic, Igor T. [1 ]
Lin, Andrew [1 ]
Pentsova, Elena [1 ]
Miller, Alex [1 ]
Newton, Adam [1 ]
Gonzalez, Ashley [1 ]
Mellinghoff, Ingo K. [1 ]
Kaley, Thomas Joseph [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2087
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Fabio M. Iwamoto
    Antonio M. Omuro
    Jeffrey J. Raizer
    Craig P. Nolan
    Adília Hormigo
    Andrew B. Lassman
    Igor T. Gavrilovic
    Lauren E. Abrey
    Journal of Neuro-Oncology, 2008, 87 : 85 - 90
  • [42] A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Iwamoto, Fabio M.
    Omuro, Antonio M.
    Raizer, Jeffrey J.
    Nolan, Craig P.
    Hormigo, Adilia
    Lassman, Andrew B.
    Gavrilovic, Igor T.
    Abrey, Lauren E.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 87 (01) : 85 - 90
  • [43] Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma
    Gruber, ML
    Buster, WP
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01): : 33 - 38
  • [44] A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.
    Wang, Xin
    Ellenbogen, Yosef
    Mojica, Christianne
    Matos, Gustavo Duarte Ramos
    Alsajjan, Roa
    Ramos, Ronald
    Climans, Seth Andrew
    Voisin, Mathew
    Patil, Vikas
    Baker, Stephanie
    Chan, Yin-Ling
    Muniz, Thiago Pimentel
    Gao, Andrew
    Wang, Ben X.
    Zadeh, Gelareh
    Mason, Warren P.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] PHASE II TRIAL OF DOSE-DENSE 1 WEEK ON/1 WEEK OFF TEMOZOLOMIDE FOR PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
    Han, Seunggu
    Molinaro, Annette
    Berger, Mitchel
    Prados, Michael
    Chang, Susan
    Clarke, Jennifer
    Butowski, Nicholas
    NEURO-ONCOLOGY, 2013, 15 : 111 - 111
  • [46] A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
    Aregawi, Dawit
    Kreisl, Teri N.
    Innis, Ellen
    Fine, Howard A.
    NEURO-ONCOLOGY, 2014, 16
  • [47] A phase II trial of sunitinib in patients with recurrent high-grade glioma
    Chaskis, C.
    Sadones, J.
    Michotte, A.
    Dujardin, M.
    Everaert, H.
    Neyns, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
    DuBois, Steven G.
    Mosse, Yael P.
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    McGovern, Renee
    Groshen, Susan
    Bagatell, Rochelle
    Maris, John M.
    Twist, Clare J.
    Goldsmith, Kelly
    Granger, M. Meaghan
    Weiss, Brian
    Park, Julie R.
    Macy, Margaret E.
    Cohn, Susan L.
    Yanik, Greg
    Wagner, Lars M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Luo, Chunqiao
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Marachelian, Araz
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6142 - 6149
  • [49] LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS
    Bang, Andrew
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S26 - S27
  • [50] Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
    Bang, A.
    Mahmood, U.
    Chen, Y. H.
    Mak, R. H.
    Lorch, J.
    Hanna, G. J.
    Sridharan, V.
    Busse, P. M.
    Willers, H.
    Mamon, H. J.
    Yoo, H. J.
    Pai, S. I.
    Wirth, L.
    Haddad, R. I.
    Chau, N.
    Schoenfeld, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E363 - E363
12345